Key Takeaways Axsome reported Q3 loss of $0.94 per share, missing estimates but improving from last year's $1.34 loss.Revenues climbed 63% to $171M, led by 69% growth in Auvelity sales and steady gains for Sunosi.Symbravo recorded $2.1M in sales, while Axsome filed an sNDA for Auvelity in Alzheimer's agitation.Axsome Therapeutics (AXSM) incurred a loss of 94 cents per share in the third quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 82 cents. The company had incurred a loss of $1.34 p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45- ...

Axsome Therapeutics (NasdaqGM:AXSM) Q3 2025 Earnings Call November 03, 2025 08:00 AM ET Speaker2Good morning and welcome to the Axsome Therapeutics third quarter 2025 earnings conference call. My name is Darrell, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, there will be a question-and-answer session, and instructions will be given at that time. Please note that this call is being recorded. I would now like to hand the call over to Darren Opl ...

axsome 3Q 2025 Corporate Presentation November 3, 2025 Forward looking statements & safe harbor Certain matters discussed in this presentation are "forward-looking statements". The Company may, in some coses, use terms such as "potential," "continue," "estimates," "anticipates;" "expects," "plans," "intends," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and ...

Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY ® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI ® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer's disease agitation submitted to the FDA Co ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer’s disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Axsome The ...

核心事件 - 投资者权益律师事务所Halper Sadeh LLC正在调查Axsome Therapeutics公司某些高管和董事是否违反了对股东的信义义务 [1] - 调查涉及Axsome Therapeutics公司纳斯达克股票代码AXSM [1][5] - 长期股东可能寻求公司治理改革、资金返还、法院批准的财务激励奖项或其他救济和利益 [2] 股东权利与行动 - 股东参与有助于改善公司政策、实践和监督机制以创造更透明、负责和有效管理的组织从而提升股东价值 [3] - 股东可通过联系律师事务所探讨权利行使方式联系电话(212) 763-0060或邮件sadeh@halpersadeh com及zhalper@halpersadeh com [2][5] - 律师事务所按或有收费基准处理案件股东无需承担自付法律费用或开支 [2] 律师事务所背景 - Halper Sadeh LLC代表全球成为证券欺诈和公司不当行为受害者的投资者 [4] - 该所律师在实施公司改革和为受欺诈投资者追回数百万美元方面发挥重要作用 [4] - 该律所地址为纽约世界贸易中心85层 [5][10]

公司发展阶段 - 公司已从研发阶段企业转型为神经科学公司 [1] - 目前有三款药物正在进行商业化营销 [1] - 公司拥有丰富的后期阶段产品管线 [1] 财务业绩 - 公司已公布2025年第三季度财报 [1]

公司业务转型 - Axsome Therapeutics 正从一家研发阶段公司向神经科学公司演变 [1] - 公司目前已有三款药物上市销售 [1] - 公司拥有丰富的后期研发管线 [1] 财务表现 - 公司公布了2025年第三季度财报 [1]